Dexmedetomidine hydrochloride for dysautonomia, familial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Nov 2023: Trial registered, NCT06128356
  2. 1 Jun 2024: Trial started, NCT06128356

The trials

NCT06128356: Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

State
Under way
Phase
Phase 2
People
5 taking part
Started
1 Jun 2024
Primary completion
Sep 2028
Arms
Sublingual dexmedetomidine
Results
None posted
  1. 13 Nov 2023: Trial registered
  2. 1 Jun 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as BXCL501 (dexmedetomidine HCl), Cepedex, Dexdor, Dexmedetomidine Sublingual, Igalmi, Precedex, Sedadex, Sileo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.